Indian pharma companies set to see 9-11% growth in FY25, says Icra

According to a report by ICRA, Indian pharmaceutical companies are expected to grow by 9-11% in FY25, driven by increased demand for generic drugs and robust domestic sales. The sector benefits from its focus on R&D, diversification into biosimilars, and a strong regulatory framework. Although challenges like price erosion in the U.S. market persist, Indian pharma companies are adapting by targeting newer, more profitable markets. This projected growth reflects the industry's resilience and ability to navigate global headwinds effectively.